The mental health and wellbeing of our people is vitally important. It is a natural extension of our company’s purpose to discover new ways to improve and extend people’s lives. Our ambition at ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

For the estimated 2.8 million people 1 living with multiple sclerosis (MS) worldwide, diagnosis is life-altering and can be overwhelming. The symptoms, including loss of vision, movement and sensation ...

Learn about the launch of our new state-of-the-art space, built to accelerate innovation from the inside out and provide new solutions for employees, partners and ultimately, our patients. On a crisp ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

この資料は、ノバルティス（スイス・バーゼル）が2025年4月30日（現地時間）に発表したものを日本語に翻訳（要約）したもので、参考資料として提供するものです。資料の内容および解釈に ...

The world has entered a new era of cancer care – and as scientific advances have dramatically improved outcomes, patients are more informed and empowered than ever to be their own treatment advocates.

Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD 1. Read on to learn more about patient populations at risk. May 19, 2025 Elevated lipoprotein(a), also ...

Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to ...